NASDAQ:OTLK Oncobiologics Q3 2025 Earnings Results & Report $0.41 -0.03 (-6.16%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$0.41 0.00 (0.00%) As of 11/13/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Oncobiologics missed analyst expectations on both earnings and revenue in its Q3 2025 results, released August 14, 2025. The company reported EPS of -$0.44 versus the -$0.42 consensus estimate, while revenue of $1.51 million fell short of the $1.66 million estimate by $157.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateAugust 14, 2025TimeBefore Market OpensConference Call12:00 AM ET Oncobiologics EPS ResultsActual EPS-$0.44Consensus EPS -$0.42Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersOncobiologics Revenue ResultsActual Revenue$1.51 millionExpected Revenue$1.66 millionBeat/MissMissed by -$157.00 thousandYoY Revenue GrowthN/AUpcoming EarningsOncobiologics' Q4 2026 earnings is estimated for Friday, December 18, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, December 24, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Oncobiologics Q3 2025 Earnings FAQ Did Oncobiologics beat earnings estimates for Q3 2025? Oncobiologics (NASDAQ:OTLK) reported earnings of -$0.44 per share for Q3 2025, missing the consensus estimate of -$0.42. The report was announced on Thursday, August 14, 2025. What was Oncobiologics' revenue for Q3 2025? Oncobiologics reported revenue of $1.51 million for Q3 2025, against a consensus estimate of $1.66 million. When is Oncobiologics' next earnings date? Oncobiologics' next earnings date is estimated for Friday, December 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Oncobiologics on the company's earnings history page. Oncobiologics Earnings HeadlinesAnalyzing Entrada Therapeutics (NASDAQ:TRDA) & Oncobiologics (NASDAQ:OTLK)November 14 at 2:18 AM | americanbankingnews.comAnalyzing Oncobiologics (OTLK) & Its PeersNovember 7, 2026 | americanbankingnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 15 at 1:00 AM | Weiss Ratings (Ad)Outlook Therapeutics Names Greg DiPasquale Chief Commercial OfficerOctober 9, 2026 | globenewswire.comOutlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor DiscussionOctober 6, 2026 | globenewswire.comOutlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)October 1, 2026 | globenewswire.comSee More Oncobiologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncobiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncobiologics and other key companies, straight to your email. Email Address About OncobiologicsOncobiologics (NASDAQ:OTLK) changed its name to Outlook Therapeutics, Inc. in 2018 and trades under the symbol OTLK. The biotechnology company focuses on developing and commercializing treatments for eye diseases.Its lead product, Lytenava (bevacizumab gamma), is an ophthalmic formulation of bevacizumab developed to treat neovascular age-related macular degeneration, also known as wet AMD. The company has pursued regulatory approvals and commercialization of the treatment in the United States and Europe.Before shifting its focus to ophthalmology, the company worked on developing biosimilar medicines. Its current business is centered on Lytenava and its ophthalmic development program.View Oncobiologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
